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Neoadjuvant therapy in relation to 
lymphadenectomy and resection 
margins during surgery for 
oesophageal cancer
Joonas H. Kauppila  1,2, Karl Wahlin1, Pernilla Lagergren3 & Jesper Lagergren1,4
Differences in lymph node yield and tumour-involved resection margins comparing neoadjuvant 
therapy plus surgery with surgery alone for oesophageal cancer are unclear. Patients who underwent 
oesophageal cancer surgery in Sweden in 1987–2010 were included. Patients treated with neoadjuvant 
therapy were compared with those who underwent surgery alone. Outcomes were the number of 
examined lymph nodes (main outcome), number metastatic lymph nodes, and resection margin status. 
Rate ratios (RRs) and 95% CIs of lymph node yield were calculated by Poisson regression, and odds 
ratios (ORs) and 95% CIs of resection margin status by multivariable logistic regression, both adjusted 
for confounders. Among 1818 patients, 587 (32%) had received neoadjuvant therapy and 1231 (68%) 
had not. Lymph node yield was lower in the neoadjuvant therapy group (median 6 versus 8; adjusted 
RR 0.75, 0.73–0.78). Fewer metastatic nodes were identified following neoadjuvant therapy (median 
0 versus 1; adjusted RR 0.76, 0.69–0.84). Neoadjuvant therapy associated to decreased risk of tumour-
involved resection margins when adjusted for confounders except T-stage (OR 0.52, 0.38–0.70), but 
the association did not remain after adjustment for T-stage (OR 0.91, 0.64–1.29). Neoadjuvant therapy 
seems to decrease the lymph node yield and decrease the risk of tumour-involved resection margins by 
shrinking primary tumour.
The curatively intended treatment of most patients with oesophageal cancer includes oesophageal resection 
with lympadenectomy1. In the recent decade, the routine addition of neoadjuvant chemotherapy or chemoradi-
otherapy to surgery and centralization of surgery to fewer centres have improved the 5-year survival in oesoph-
ageal cancer1,2. More extensive lymphadenectomy has been associated with better survival in some studies3,4, 
but the independent prognostic role of more extensive lymphadenectomy has been challenged by recent studies 
controlling for confounding by surgeon volume5,6. The debate whether the differences in opportunities of lym-
phadenectomy between the main surgical approaches, i.e. open transthoracic, transhiatal, or minimally invasive 
oesophagectomy, influence the survival is also ongoing, but no clear survival differences have been shown thus 
far7–10. The use of neoadjuvant therapy might complicate the assessment of lymphadenectomy and how it may 
influence survival. By shrinking lymph nodes, it is possible that neoadjuvant therapy makes the removal or detec-
tion of nodes more difficult. The few investigations examining the association between neoadjuvant therapy and 
the number of resected lymph nodes show contradictory findings, with some studies reporting a reduction in the 
number of nodes, while other studies do not11–17. A main aim of neoadjuvant therapy is to shrink the primary 
tumour. This in turn could facilitate radical (R0) resection, but this question requires more research18.
Taken together, there is a need to better understand how neoadjuvant therapy influences the lymph node yield 
and resection margins status in oesophageal cancer patients who undergo surgery. The aim of this study was to 
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clarify these questions while taking confounding into account, including the potentially critical factors surgeon 
volume and tumour stage.
Methods
Study design. In this population-based and nationwide Swedish cohort study from 1987 to 2010, the study 
exposure was the administration of neoadjuvant therapy (yes or no) before surgery for oesophageal cancer. The 
primary outcome was the number of removed and examined lymph nodes, while secondary outcomes were the 
number of removed and examined metastatic lymph nodes and the rate of radical resection without microscopic 
or macroscopic residual tumour in the resection margin (R0-resection).
Cohort. Earlier versions of this cohort have been used for other clinical studies examining oesophageal cancer 
surgery6,19,20, and the updated current version has also been described elsewhere21. Briefly, the cohort included 
98% of all oesophageal cancer patients who underwent curatively intended treatment in Sweden between 1987 
and 2010. The patients were selected by combining data from the Swedish Cancer Registry for identifying all 
patients with oesophageal cancer, and the Swedish Patient Registry for selecting only patients who had undergone 
oesophagectomy. The information from these registers was linked for all individual patients using the Swedish 
personal identity number, a unique 10-digit identifier assigned to each Swedish resident upon birth or immigra-
tion, which is a well-validated tool for research purposes22. For collection of more detailed clinical data, including 
the number of nodes, resection margin status, surgeon volume and tumour stage, surgery charts and pathology 
records were retrieved from all hospitals conducting oesophageal cancer surgery in Sweden during the study 
period. The data retrieved from the medical records followed a detailed predefined protocol, an assessment that 
has been validated for high concordance20. Comorbidity data were retrieved from the Patient Registry and were 
defined and categorized using the most recently updated and well-validated Charlson Comorbidity Index23. The 
study was approved by The Regional Ethical Review Board in Stockholm, Sweden. All methods were carried out 
in accordance with relevant guidelines and regulations. Individual informed consent was not acquired as this is 
not necessary for this type of study (based on registry data and medical records) according to Swedish law.
Treatment. The treatments, including neoadjuvant treatment, of the individual patients were agreed upon by 
surgeons and oncologists (typically in multidisciplinary meetings) together with the patients. The most frequently 
used neoadjuvant therapy was chemoradiotherapy, consisting of cisplatin- and fluorouracil-based chemotherapy 
supplemented by radiotherapy in 2Gy fractions for a total dose of up to 40Gy, but also radiotherapy and chemo-
therapy alone were used. Of those 1767 (97%) patients with data on surgical approach available, transthoracic 
resection with intrathoracic anastomosis was the dominating (96%) surgical procedure and a gastric tube which 
was pulled up and anastomosed to the proximal oesophagus was the preferred reconstruction. Only 4% of the 
patients underwent transhiatal oesophagectomy. No consensus on the extent of lymphadenectomy existed during 
the study period.
Statistical analysis. All statistical analyses were carried out according to an a priori specified study protocol, 
defining and categorizing all exposures, outcomes and covariates. Because of the logarithmic distribution of the 
lymph node variables, Poisson regression was used to estimate ratios (RRs) with 95% confidence intervals (CIs) 
for associations between neoadjuvant therapy and number of removed and examined lymph nodes and metastatic 
lymph nodes. A stratified analysis was performed for T-stage groups. A subgroup analysis was conducted com-
paring patients receiving neoadjuvant chemoradiotherapy (excluding unknown neoadjuvant therapy and neo-
adjuvant chemotherapy or radiotherapy) to patients receiving surgery only. Multivariable logistic regression was 
used to calculate odds ratios (ORs) with 95% CIs for associations between neoadjuvant therapy and non-radical 
resection margins (R1/R2). In all models, the following covariates were selected as potential confounders: 1) age 
(continuous variable, per year), 2) calendar year (continuous variable), 3) tumour histology (adenocarcinoma or 
squamous cell carcinoma), 4) comorbidity (Charlson Comorbidity score 0, 1, or ≥2), 5) surgeon volume (0–6, 
7–16, 17–46, or ≥47 cumulative number of oesophagectomies during the study period), and 6) pathological 
T-stage (T0-T1, T2, T3, T4, or Tx). Missing data covariate data were few (Table 1) and therefore handled by con-
ducting a complete case analysis. The statistical software IBM SPSS v24.0 (IBM Corp., Armonk, NY) was used for 
all statistical analyses.
Results
Patient characteristics. Among 1821 patients included in the cohort, 1818 had information on neoad-
juvant therapy and were selected for the present study. Of these, 587 (32%) had neoadjuvant therapy prior to 
surgery and 1231 (68%) had surgery alone. The regimen of neoadjuvant therapy was available for 516 patients, 
of which 354 (69%) received neoadjuvant chemoradiotherapy, 113 (22%) received neoadjuvant radiation ther-
apy, and 49 (9%) received neaodjuvant chemotherapy. Characteristics of the study participants are presented 
in Table 1. The neoadjuvant therapy group contained younger patients and a larger proportion of patients with 
squamous cell carcinoma and tumours of favourable pathological tumour stage than patients in the surgery alone 
group, while comorbidity was equally distributed. The characteristics of the patients in the subgroup analysis 
of neoadjuvant chemoradiotherapy versus surgery were highly similar compared to the main analysis, and are 
shown in the Supplementary Table S1.
Lymph node yield. Among all study participants, 1347 (74%) had information on the number of removed 
and examined lymph nodes and were thus included in this analysis. The distribution of number of removed 
and examined lymph nodes was skewed (Fig. 1). The number of nodes was lower among patients having had 
neoadjuvant therapy (median 6, interquartile range 3–12), compared to those having undergone surgery alone 
(median 8, interquartile range 5–16). The difference was confirmed in the fully adjusted Poisson regression for all 
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pathological T-stages combined showing a 25% decrease in the number of lymph nodes after neoadjuvant ther-
apy compared to surgery only (RR 0.75, 95% CI 0.73–0.78, and for each pathological T-stage analysed separately 
(Table 2). In the subgroup analysis of patients undergoing neoadjuvant chemoradiotherapy compared to those 
undergoing surgery, the difference was even more pronounced (32% reduction) in the fully adjusted Poisson 
regression model (RR 0.68, 95% CI 0.65–0.72, Table 2).
The number of removed and examined metastatic lymph nodes was also lower among patients who had 
received neoadjuvant therapy (median 0, interquartile range 0–2), when compared to patients who had 
Surgery alone
Neoadjuvant therapy 
and surgery Total
Number (%) Number (%) Number (%)
Total 1231 (68) 587 (32) 1818 (100)
Time period
1987–1995 412 (34) 200 (33) 612 (34)
1995–2002 451 (37) 181 (29) 632 (35)
2003–2010 368 (30) 206 (36) 574 (32)
Age (median, interquartile range) 67 (60–73) 64 (58–70) 66 (59–72)
Sex
Male 914 (74) 445 (76) 1359 (75)
Female 317 (26) 142 (24) 459 (25)
Charlson’s Comorbidity Index
0 740 (60) 361 (62) 1101 (61)
1 305 (25) 139 (24) 444 (24)
≥2 186 (15) 87 (15) 273 (15)
Type of resection
Transthoracic 1142 (93) 546 (93) 1688 (93)
Transhiatal 57 (5) 22 (4) 79 (4)
Missing 32 (3) 19 (3) 51 (3)
Histology
Adenocarcinoma 594 (48) 197 (34) 791 (44)
Squamous cell carcinoma 634 (52) 389 (66) 1023 (56)
Missing 3 (0) 1 (0) 4 (0)
Pathological T-stage
T0–1 211 (17) 211 (36) 420 (23)
T2 209 (17) 135 (23) 344 (19)
T3 534 (43) 149 (25) 683 (38)
T4 95 (8) 26 (4) 121 (7)
Tx 182 (15) 66 (11) 248 (14)
Cumulative surgeon volume
Very low ( < 6) 336 (27) 153 (26) 489 (27)
Low (7–16) 245 (20) 150 (26) 395 (22)
Mid (17–46) 285 (23) 158 (27) 443 (24)
High (≥47) 328 (27) 105 (18) 433 (24)
Missing 37 (2) 21 (4) 58 (3)
Number of removed nodes
Median (Interquartile range) 8 (5–16) 6 (3–12) 7 (4–15)
Number of positive nodes
Median (Interquartile range) 1 (0–4) 0 (0–2) 1 (0–3)
Resection margins
R0 816 (66) 456 (78) 1272 (70)
R1/R2 209 (17) 72 (12) 281 (15)
Missing 206 (17) 59 (10) 265 (15)
Type of neoadjuvant therapy
Chemoradiotherapy N/A 354 (60) 354 (60)
Radiotherapy N/A 113 (19) 113 (19)
Chemotherapy N/A 49 (8) 49 (8)
Missing N/A 71 (12) 71 (12)
Table 1. Characteristics of 1818 patients who underwent surgery for oesophageal cancer with or without 
neoadjuvant therapy in Sweden in 1987–2010.
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undergone surgery alone (median 1, interquartile range 0–4). This difference was confirmed in the fully adjusted 
model showing 24% decrease in number of metastatic lymph nodes after neoadjuvant therapy, compared to sur-
gery only (RR 0.76, 95% CI 0.69–0.84, Table 3). The stratified analysis showed that the association was strongest 
in the pathological T-stage 3 category (Table 3). In the subgroup analysis of patients undergoing neoadjuvant 
chemoradiotherapy compared to those undergoing surgery, the difference was even more pronounced (32% 
reduction) in the fully adjusted Poisson regression model (RR 0.68, 95% CI 0.60–0.77, Table 3).
Resection margins. A total of 1553 (85%) patients had data on resection margins and were included in 
the analysis of this outcome. The proportion of patients with tumour-involved resection margins (R1/R2) was 
lower (14%) in the neoadjuvant therapy group compared to surgery alone group (20%). After adjustment for 
confounders, except for T-stage, neoadjuvant therapy was associated with a decreased risk of tumour-involved 
resection margins (OR 0.52, 95% CI 0.38–0.70. When tumour T-stage was included in the fully adjusted model, 
no association remained (OR 0.91, 95% CI 0.64–1.29) (Table 4). Additionally, no associations between neoadju-
vant therapy and resection margin status were found in the analysis stratified by T-stage categories (Table 4). In 
the subgroup analysis of patients undergoing neoadjuvant chemoradiotherapy compared to those undergoing 
surgery, the results were highly similar to the main analysis (Table 3).
Discussion
The results of this study suggest that any neoadjuvant therapy, as well as neoadjuvant chemoradiotherapy, reduces 
the lymph node yield and reduces the proportion of tumour-involved resection margins in relation to tumour 
stage during surgery for oesophageal cancer. The latter association seems to be mediated by shrinkage of the 
primary tumour.
Among methodological strengths of the study are the population-based nationwide design, the complete and 
validated data collection, and the large sample size. To counteract confounding, which is an inherent source if bias 
in observation studies, adjustments were made for several key covariates. Lymph node yield increases with surgi-
cal experience21, and thus surgeon volume was adjusted for. Changes over time regarding surgical and oncological 
Figure 1. The distribution of number of removed and examined lymph nodes is shown for patients with 
surgery only (A) and patients undergoing neoadjuvant therapy before surgery (C). The distribution of number 
metastatic lymph nodes is shown for patients with surgery only (B) and patients undergoing neoadjuvant 
therapy before surgery (D).
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treatments and pathological examination of the surgical specimen were taken into account by adjusting for calen-
dar year of the surgery. Because surgeons might prefer less radical surgery in frail patients, patient age and comor-
bidities were adjusted for. Surgeons operating on patients with more advanced tumours, including advanced 
tumours down-staged by neoadjuvant therapy, might conduct more radical surgery compared to less advanced 
Model
Patients 
Number
Surgery alone Rate 
ratio (95% CI)
Neoadjuvant therapy 
Rate ratio (95% CI)
Crude 1347 1.00 (reference) 0.77 (0.74–0.80)
Adjusteda 1307 1.00 (reference) 0.72 (0.69–0.75)
Adjustedb 1307 1.00 (reference) 0.75 (0.73–0.78)
Stratified by T-stagea
T0–1 319 1.00 (reference) 0.83 (0.77–0.89)
T2 296 1.00 (reference) 0.72 (0.66–0.77)
T3 578 1.00 (reference) 0.75 (0.71–0.80)
T4 92 1.00 (reference) 0.72 (0.60–0.87)
Tx 22 1.00 (reference) 0.48 (0.37–0.64)
Subgroup analysis of patients with neoadjuvant chemoradiotherapy 
versus surgery
Crude 1184 1.00 (reference) 0.73 (0.70–0.76)
Adjusteda 1156 1.00 (reference) 0.65 (0.62–0.68)
Adjustedb 1156 1.00 (reference) 0.68 (0.65–0.72)
Patients with neoadjuvant chemoradiotherapy versus surgery 
stratified by T-stagea
T0–1 274 1.00 (reference) 0.82 (0.75–0.89)
T2 248 1.00 (reference) 0.62 (0.56–0.68)
T3 531 1.00 (reference) 0.68 (0.62–0.74)
T4 83 1.00 (reference) 0.48 (0.35–0.67)
Tx 20 1.00 (reference) 0.42 (0.30–0.58)
Table 2. Neoadjuvant therapy plus surgery compared to surgery alone for oesophageal cancer in relation to 
number of removed lymph nodes, expressed as rate ratios and 95% confidence intervals (CI). aAdjusted for age 
(per year), calendar year, Charlson’s Comorbidity Index, histology and surgeon volume. bAdjusted for age (per 
year), calendar year, Charlson’s Comorbidity Index, histology, surgeon volume and T-stage.
Model
Patients 
Number
Surgery alone Rate 
ratio (95% CI)
Neoadjuvant therapy 
Rate ratio (95% CI)
Crude 1268 1.00 (reference) 0.53 (0.49–0.58)
Adjusteda 1228 1.00 (reference) 0.56 (0.51–0.61)
Adjustedb 1228 1.00 (reference) 0.76 (0.69–0.84)
Stratified by T-stagea,c
T0–1 290 1.00 (reference) 1.41 (1.04–1.91)
T2 279 1.00 (reference) 0.99 (0.82–1.19)
T3 549 1.00 (reference) 0.55 (0.48–0.63)
T4 88 1.00 (reference) 1.18 (0.89–1.57)
Subgroup analysis of patients with neoadjuvant chemoradiotherapy 
versus surgery
Crude 1106 1.00 (reference) 0.44 (0.39–0.49)
Adjusteda 1078 1.00 (reference) 0.45 (0.40–0.51)
Adjustedb 1078 1.00 (reference) 0.68 (0.60–0.77)
Patients with neoadjuvant chemoradiotherapy versus surgery stratified 
by T-stagea,c
T0–1 245 1.00 (reference) 1.31 (0.93–1.84)
T2 232 1.00 (reference) 0.78 (0.61–0.99)
T3 502 1.00 (reference) 0.55 (0.46–0.66)
T4 79 1.00 (reference) 0.52 (0.29–0.92)
Table 3. Neoadjuvant therapy plus surgery compared to surgery alone for oesophageal cancer in relation to 
number of metastatic lymph nodes, expressed as rate ratios and 95% confidence intervals (CI). aAdjusted for age 
(per year), calendar year, Charlson’s Comorbidity Index, histology and surgeon volume. bAdjusted for age (per 
year), calendar year, Charlson’s Comorbidity Index, histology, surgeon volume and T-stage. cEstimates for Tx 
are not shown as they could not be calculated because of small numbers.
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tumours not receiving neoadjuvant therapy. Therefore, the results were adjusted for and stratified by T-stage. We 
did not have data on clinical T-stage, but could only assess pathological T-stage. In addition to the surgeon, the 
pathologist also has an important role in the final lymph node count24. Therefore, lymph node yield was labelled 
as removed and examined nodes. The smallest nodes in the specimen are harder to detect25, but yet up to 30–40% 
of the nodal metastases in gastroesophageal cancer are found in small (<5 mm) nodes24,26,27. This might affect the 
number of removed and examined lymph nodes in the present and previous studies evaluating the association 
between neoadjuvant therapy and lymph node yield. A weakness in the present study is the low median number 
of removed and examined lymph nodes, which might be considered a poor oncological resection. This might 
reflect the lack of centralization and consensus regarding the extent of lymphadenectomy in Sweden during most 
of the long study period. However, it is unlikely that the extent of lymphadenectomy would differ in those under-
going neoadjuvant therapy or surgery alone after adjustments for calendar year and surgeon volume.
The present study indicates that neoadjuvant therapy reduces the number of removed and examined lymph 
nodes. The available literature on this topic is limited. Randomized clinical trials have shown that neoadjuvant 
therapy increases the resectability of oesophageal cancer, but without reporting the lymph node yield28–36. Two 
post-hoc analyses of randomized clinical trials from the Netherlands (n = 320) and France (n = 195), and one 
French hospital-based cohort study of R0-resected patients (n = 536), suggested a reduced lymph node yield 
after neoadjuvant therapy compared to surgery alone for oesophageal cancer11,16,17. A register-based study from 
the United States on patients undergoing oesophagectomy for gastroesophageal cancers (n = 18,777) suggested 
that neoadjuvant therapy was associated with a decreased likelihood of obtaining 15 or more nodes, but did not 
assess specific numbers of nodes37. Another register-based study from the United States (n = 5,805), a Taiwanese 
register-based study (n = 2,151), and a hospital-based study (n = 111) from the United States found no associa-
tion between neoadjuvant therapy and lymph node yield in oesophageal cancer14,15,38, but none of these studies 
adjusted the results for surgeon volume, or other potential confounders.
Neoadjuvant therapy was also associated with a decreased number of removed and examined metastatic 
lymph nodes in this study, which has also been observed earlier and is one of the goals of neoadjuvant therapy11. 
The stratified analysis showed that the association is the strongest in the high-T-stage category, suggesting that 
neoadjuvant therapy could reduce the number of lymph node metastases even when no significant down-staging 
occurs in the primary tumour.
The risk of tumour-involved resection margins was decreased in the neoadjuvant therapy group of the present 
study, which is in line with some previous studies28–36,39. The disappearance of the association after adjustment 
and stratification for T-stage suggests, in line with a previous study40, that the influence of neoadjuvant therapy on 
tumour-involved resection margins is mediated by shrinkage of the primary tumour.
This study has some potential clinical and research implications. The number of removed lymph nodes during 
surgery is considered an indicator of the quality of the esophagectomy41. This study suggests that the expected 
lymph node yield should be 25% lower after neoadjuvant therapy (and 32% lower after neoadjuvant chemoradio-
therapy) than after surgery alone, even when adjusting for important confounders surgeon experience and time. 
Model
Patients 
Number
Surgery alone Odds 
ratio (95% CI)
Neoadjuvant therapy 
Odds ratio (95% CI)
Crude 1553 1.00 (reference) 0.62 (0.46–0.83)
Adjusteda 1553 1.00 (reference) 0.52 (0.38–0.70)
Adjustedb 1553 1.00 (reference) 0.91 (0.64–1.29)
Stratified by T-stagea,c
T0–1 417 1.00 (reference) 1.90 (0.28–12.87)
T2 336 1.00 (reference) 1.03 (0.50–2.14)
T3 662 1.00 (reference) 0.95 (0.61–1.48)
T4 113 1.00 (reference) 0.47 (0.16–1.39)
Subgroup analysis of patients with neoadjuvant chemoradiotherapy 
versus surgery
Crude 1343 1.00 (reference) 0.56 (0.39–0.81)
Adjusteda 1343 1.00 (reference) 0.50 (0.34–0.73)
Adjustedb 1343 1.00 (reference) 0.98 (0.63–1.54)
Patients with neoadjuvant chemoradiotherapy versus surgery stratified 
by T-stagea,c
T0–1 352 1.00 (reference) 1.60 (0.19–13.52)
T2 274 1.00 (reference) 0.62 (0.22–1.77)
T3 593 1.00 (reference) 1.07 (0.61–1.90)
T4 101 1.00 (reference) 1.71 (0.32–9.11)
Table 4. Neoadjuvant therapy plus surgery compared to surgery alone for oesophageal cancer in relation to 
positive resection margins, expressed as odds ratios and 95% confidence intervals (CI). aAdjusted for age (per 
year), calendar year, Charlson’s Comorbidity Index, histology and surgeon volume. bAdjusted for age (per year), 
calendar year, Charlson’s Comorbidity Index, histology, surgeon volume and T-stage. cEstimates for Tx are not 
shown as they could not be calculated because of small numbers.
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This might not be a concern because recent large studies have not found any survival benefit of more extensive 
lymphadenectomy after neoadjuvant therapy11, or altogether in oesophageal cancer5,6. On the other hand, a recent 
large study from the Netherlands showed better survival (adjusted HR 0.77, 95% CI 0.68–0.86) after more exten-
sive lymphadenectomy in oesophageal cancer after neoadjuvant chemoradiotherapy42. However, it is still unclear 
whether the previously suggested cut-offs for adequate lymph node yield are relevant in the neoadjuvant therapy 
era, or whether they are a proxy for skill and experience of the surgeon6. The association between neoadjuvant 
therapy and lymph node yield also indicates that future studies assessing lymphadenectomy should adjust for the 
use of neoadjuvant therapy.
In conclusion, this nationwide and population-based study with adjustment for several confounders indi-
cates that neoadjuvant therapy reduces the number of removed and examined lymph nodes and the risk of 
tumour-involved resection margins in patients who undergo surgery for oesophageal cancer. These findings 
might contribute to changing the view regarding the need for a certain lymph node yield following neoadjuvant 
therapy and that neoadjuvant therapy should be taken into account in analyses of lymph node yield in future 
research.
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